Blood Levels of Monoamine Precursors and Smoking in Patients with Schizophrenia
Open Access
- 30 August 2016
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 4, 182
Abstract
Smoking is highly prevalent in patients with schizophrenia and exerts a negative impact on cardiovascular mortality in these patients. Smoking has complex interactions with monoamine metabolism through the ability of cigarette smoke to suppress Type 1 T helper cell (Th1) type immunity, the immunophenotype that is implicated in phenylalanine hydroxylase (PAH) dysfunction and tryptophan breakdown to kynurenine via indoleamine 2,3-dioxygenase (IDO). Nicotine also induces tyrosine hydroxylase gene (TH) expression, leading to increased synthesis of catecholamines. Furthermore, there is evidence for PAH dysfunction in schizophrenia. This study aimed to compare the plasma levels of selected monoamine precursors and their metabolites in smokers vs non-smokers in a large sample of patients with schizophrenia. We measured plasma phenylalanine, tyrosine, tryptophan and kynurenine levels using high-performance liquid chromatography (HPLC) and calculated phenylalanine: tyrosine (Phe: Tyr) and kynurenine: tryptophan (Kyn: Trp) ratios in 920 patients with schizophrenia. Analysis of variance (ANOVA) and linear regression analyses were used to compare these endpoints between 3 groups of patients with schizophrenia; 1) current smokers, 2) past smokers and 3) non-smokers. There were significant differences among the three groups with regards to tyrosine levels [F(2,789)=3.77, p=0.02], with current smokers having lower tyrosine levels when compared to non-smokers (p=0.02). Kynurenine levels and Kyn :Trp ratio were different among the 3 groups [F (2,738)=3.17, p=0.04, F(2,738)=3.61, p=0.03] with current smokers having lower kynurenine levels (p=0.04) and higher Kyn: Trp ratio (p=0.02) when compared to past smokers. These findings need to be replicated with protocols that include healthy controls to further elucidate the neurobiological underpinnings of altered tyrosine and kynurenine levels in smokers. Results do suggest potential molecular links between schizophrenia and smoking that may represent biomarkers and treatment targets for reducing an important modifiable cause of general morbidity and mortality in patients with schizophrenia.Keywords
Funding Information
- American Foundation for Suicide Prevention (DIG 1-162-12)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK072488 NIDDK)
- University of Maryland (FDU.001418)
This publication has 58 references indexed in Scilit:
- 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patientsTranslational Psychiatry, 2012
- Tyrosine hydroxylase and regulation of dopamine synthesisArchives of Biochemistry and Biophysics, 2011
- Modulation of Tyrosine Hydroxylase, Neuropeptide Y, Glutamate, and Substance P in Ganglia and Brain Areas Involved in Cardiovascular Control after Chronic Exposure to NicotineInternational Journal of Hypertension, 2011
- Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause?Journal of Inherited Metabolic Disease, 2009
- Convergent patterns of association between phenylalanine hydroxylase variants and schizophrenia in four independent samplesAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008
- The activity of the immunoregulatory enzyme indoleamine 2,3-dioxygenase is decreased in smokersClinical and Experimental Immunology, 2006
- Effect of Short-Term Cigarette Smoke Exposure on Body Weight, Appetite and Brain Neuropeptide Y in MiceNeuropsychopharmacology, 2004
- Nicotine and familial vulnerability to schizophrenia: A discordant twin study.Journal of Abnormal Psychology, 2002
- Drug Interactions with Tobacco SmokingClinical Pharmacokinetics, 1999
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991